D3 Bio
Signal active
Organization
Contact Information
Overview
D3 Bio is a biotechnology company that focuses on discovering and creating medications in oncology and immunology. The company combines clinical and market data to identify shortcomings in existing conventional medicines, employs unique drug development methodologies aimed at new disease targets and delivery routes, and provides patients with therapy alternatives in immunology and oncology.
About
Industries
Biotechnology, Life Science, Pharmaceutical
Founded
2020
Employees
1-10
Headquarters locations
Asia
Social
N/A
Profile Resume
D3 Bio headquartered in Asia, operates in the Biotechnology, Life Science, Pharmaceutical sector. The company focuses on Biotechnology and has secured $6.3B in funding across 24 round(s). With a team of 1-10 employees, D3 Bio is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - D3 Bio, raised $62.0M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
Funding rounds
2
Investors
3
Lead Investors
0
Total Funding Amount
$262.0M
Details
2
D3 Bio has raised a total of $262.0M in funding over 2 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|---|---|---|---|
| 2020 | Early Stage Venture | 200.0M | ||
| 2024 | Early Stage Venture | 62.0M |
Investors
D3 Bio is funded by 10 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| D3 Bio | - | FUNDING ROUND - D3 Bio | 62.0M |
| Medicxi | - | FUNDING ROUND - Medicxi | 62.0M |
| Matrix Partners China | - | FUNDING ROUND - Matrix Partners China | 62.0M |
| D3 Bio | - | FUNDING ROUND - D3 Bio | 62.0M |
Recent Activity
There is no recent news or activity for this profile.